Biocon Biologics, Viatris Inc. get CHMP nod for Abevmy, a biosimilar to Avastin
Abevmy is abiosimilar to Roche's Avastin, prescribed for all indications including metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen, it said.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Avastin | Biotechnology | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Colorectal Cancer | Kidney Cancer | Non-Small Cell Lung Cancer | Ovarian Cancer | Ovaries | Pharmaceuticals